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INTRODUCTION
Type 2 Diabetes Mellitus is a major health problem all over the 
world. It forms more than 90% of the diabetic population1. The WHO 
has highlighted that  India would lead the world in the prevalence of 
Diabetes mellitus and would become diabetic capital of the world and 
contribute more than 20% of the world diabetic population by the year 
2025.2
          The impact of the worldwide explosion of type 2 diabetes mellitus 
(which accounts for approximately 85 to 95% of all cases of diabetes) 
will remain centered in the developing countries, since by the year 2025, 
75 % of all the people with diabetes will be in the developing countries, 
a majority in the Indian subcontinent (59 %). By 2025, there will be a 
170% increase from 84 – 228 million ,  in the developing countries.3 
India already faces a grave problem with the largest number of subjects 
with diabetes approximately 33 million in 2003 and it is expected to 
escalate further with the number increasing to 57.2 million in the year 
2025 3,4and by the year 2030 it may be 80.9 million.5  
Langley  coined  the  term autonomic  nervous  system in  1898.6 
Cardiac  autonomic  neuropathy  was  noted  nearly  100  years  ago  by 
Eichhorst  (1882).  The  autonomic  nervous  system,  through  the 
sympathetic  and parasympathetic  pathways influences every organ of 
the body. It closely integrates vital processes such as heart rate, blood 
pressure,  myocardial  contractility  and as a consequence  plays a vital 
role  in  the  regulation  of  the  cardiovascular  system.  Autonomic 
dysfunction  is  common  (40%)  in  diabetics  but  in  sharp  contrast 
symptomatic autonomic neuropathy is rare .7
Diabetes is the most common cause of autonomic neuropathy and 
autonomic damage to the heart occurs as a part of the wider spectrum of 
the autonomic neuropathy which affects most organs of the body. It is in 
the cardiovascular system that autonomic neuropathy is most noticeable 
and most easily assessed. With advent of newer methods of assessment 
of cardiac autonomic dysfunction, it is now well known that autonomic 
neuropathy could occur quite early in the course of diabetes mellitus.
It is also generally assumed that cardiac autonomic neuropathy is 
responsible for an altered perception of myocardial ischaemia, painless 
myocardial  ischaemia  and  silent  acute  myocardial  infarction.  In  a 
recently  published  study  cardiac  autonomic  neuropathy  was 
independently associated with asymptomatic coronary artery disease in 
patients with type 2 diabetics.  Autonomic neuropathy is significantly 
associated  with  diabetic  retinopathy  or  nephropathy.  Autonomic 
neuropathy usually coexists with a small fibre peripheral neuropathy 8
The diabetes control and complications trial showed that intensive 
control  of  the  blood  sugar  over  a  7  year  study  interval  reduced  the 
progression  of  diabetic  neuropathy,  retinopathy  and  nephropathy.9 
Diabetes  complicates  every  organ  and  is  the  fourth  major  cause  of 
mortality  and morbidity  worldwide.  The relationship between control 
and  complications  in  type  2  diabetes  mellitus  was  evaluated  in 
UKPDS.10   The study concluded that for every 1% decrease in HbA1c 
there was 35% reduction in the risk of microvascular complications.
The  availability  of  sensitive,  specific  and  reproducible 
noninvasive  tests  of  autonomic  function  has  enhanced  our 
understanding  of  the  prevalence,  pathophysiology  and  clinical 
manifestations of this disorder.11 Estimates of the prevalence of diabetic 
autonomic neuropathy are dependent on the criteria used for diagnosis 
and the specific population under study.  
This  study  is  aimed  at  detecting  the  autonomic  functions  in  a 
group of randomly selected type 2 diabetic patients, by simple bed side 
tests. Our better understanding on clinical and prognostic importance of 
autonomic  neuropathy  was  closely  related  to  the  widespread  use  of 
simple  non-invasive  reflex  tests.  Recognizing  cardiac  dysautonomia 
earlier can help us to prevent many dreadful complications like sudden 
death and to start on various measures to prevent its progression.
AIMS OF THE STUDY
The aims of the study are: 
1. To assess the prevalence of Cardiac Autonomic Neuropathy in a 
group of Type 2 Diabetes mellitus patients using a comprehensive 
series of standardized tests by using a cardiac autonomic nervous 
system analyzer CANS 504 
2. Attempt  to  correlate  Cardiac  Autonomic  dysfunction  with 
duration  of  Diabetes  mellitus  and  other  microvascular 
complications  like  Peripheral  neuropathy,  Nephropathy  and 
Retinopathy.
REVIEW OF LITERATURE
Diabetes mellitus is a heterogenous group of metabolic disorders 
characterized by chronic hyperglycemia. The effect of diabetes mellitus 
include long term damage,  dysfunction and failure of  various organs 
especially the eyes, kidneys, heart and blood vessels.1
The worldwide prevalence of DM has risen dramatically over the 
past  2  decades.  There  is  considerable  geographic  variation  in  the 
incidence of both type 1 and type 2 DM. The results of the prevalence 
studies of DM in India were systematically reviewed with emphasis on 
those utilizing the standard WHO criteria for diabetes diagnosis.  The 
prevalence of diabetes in adults was found to be 2.4 % in rural and 4.0 – 
11.6  %  in  urban  dwellers.  High  frequencies  of  impaired  glucose 
tolerance, shown by these studies, ranging from 3.6 – 9.1% indicate the 
potential for further rise in prevalence of diabetes mellitus in the coming 
decades.12  Recently the WHO in consultation with an expert committee 
of the American Diabetes Association has approved a new diagnostic 
criteria for DM.
DIAGNOSTIC CRITERIA
CATEGORY FPG PPG
Normal < 100mg/dl
(5.6 mmol / L)
< 140 mg/dl
(< 7.8 mmol / L)
IFG 100 – 125 mg / dl
(5.6 – 6.9 mmol / L)
_
IGT _ 140 – 199 mg / dl
(7.8 – 11.0 mmol / 
L)
DIABETES ≥  126 mg / dl
(7.0 mmol/ L )
≥  200 mg / dl
(11.1 mmol / L )
Fasting : No caloric intake for atleast 8 hours.
When the  diagnosis  of  diabetes  is  made,  it  is  confirmed  by  a 
repeat testing done on a different day. 
Diabetic neuropathy is the commonest diabetic complication. The 
nervous system is frequently involved in diabetes mellitus, irrespective 
of the type of diabetes mellitus. Diabetes mellitus can affect the nervous 
system in the following ways:
1) Affection  of  the  nerves  (neuropathy)-  motor,  sensory, 
autonomic or mixed.
2) Affection  of  the  brain  and  spinal  cord  indirectly  by 
potentiating  atherosclerosis  and  thereby  vasculopathy 
(ischeamia/infarction)
3) Coma  as  a  result  of  diabetic  ketoacidosis,  nonketotic 
hyperosmolar  state  or  hypoglycemia  causing damage  to  the 
brain .13
ANATOMY OF THE AUTONOMIC NERVOUS SYSTEM 8,14
The most remarkable features of the autonomic nervous system 
(also called the visceral vegetative, or involuntary nervous system) is 
that a major part of it is located outside the cerebrospinal system, in 
proximity to the visceral structures that it innervates. 
In the autonomic nervous system there are always two efferent 
neurons  serving  this  fucntion  -  one  (preganglionic)  arising  from  its 
nucleus in the brainstem or spinal cord and the other (postganglionic) 
arising  from  specialized  nerve  cells  in  peripheral  ganglia.  The 
autonomic nervous system is divided into two parts the craniosacral, or 
parasympathetic and the thoracolumbar, or sympathetic.
Parasympathetic Nervous system
There are two divisions of the parasympathetic nervous system - 
cranial and sacral. 
Cranial division
It  originates  in  the  visceral  nuclei  of  the  midbrain,  pons  and 
medulla.  These  nuclei  lie  in  close  proximity  to  the  somatic  afferent 
nuclei and induce the Edinger -  Westphal  pupillary nucleus, superior 
and inferior salivatory nuclei, dorsal motor nucleus of the vagus, and 
adjacent reticular nuclei.
The preganglionic fibers of the visceral cranial nuclei course through 
the  oculomotor,  facial,  glassopharyngeal  and  vagus  nerves.  The 
preganglionic fibers from the Edinger - Westphal nucleus traverse the 
oculomotor nerve and synapse in the cilliary ganglion in the  orbit & 
axons  of  the  cilary  ganglion  cells  innervate  the  ciliary  muscle  and 
papillary sphincter.
The preganglionic fibers of the superior salivatory nucleus enter 
the facial nerve and form the greater superficial petrosal nerve, through 
which they reach the spheno - palatine ganglion, psotganglionic fibers 
from the cells of this ganglion innervate the lacrimal gland. Other fibers 
of the facial nerve traverse the tympanic cavity as the chord tympani 
and eventually join the submandibular ganglion, cells of this ganglion 
innervate the submandibular and sublingual glands.
Axons  of  the  inferior  salivatory  nerve  cells  enter  the 
glossopharyngeal  nerve  and  reach  the  otic  ganglion  through  the 
tympanic plexus and lesser superficial petrosal nerve, cells of the otic 
ganglion send fibers to the parotid gland.
Preganglionic fibers, derived from the dorsal motor nucleus of the 
vagus  and  adjacent  visceral  nuclei  in  the  lateral  reticular  formation, 
enter the vagus nerve and terminate in ganglia situated in the walls of 
many thoracic and abdominal viscera. The short post-ganglionic fibers 
that activate smooth muscle and glands of the pharynx, esophagus and 
gastrointestinal tract (up to of the descending colon) and of the heart, 
pancreas, liver, gallbladder, kidney and ureter. 
Sacral division: 
It  originates  in  the  lateral  horn  cells  of  the  second,  third,  and 
fourth sacral segments. Axons of these sacral neurons, constituting the 
preganglionic fibers, traverse the sacral nerves and synapse in ganglia 
that lie within the walls of the distal colon, bladder and other pelvic 
organs. Thus, the sacral autonomic neurons, like the cranial ones, have 
long  preganglionic  and  short  postganglionic  fibers  -  a  feature  that 
permits a circumscribed influence upon the target organ. 
Sympathetic Nervous system 
The preganglionic neurons of the sympathetic division originate 
in the intermedio-lateral cell column of the spinal gray matter, from the 
eighth cervical to the second lumbar segments. 
Axons  of  the  nerve  fibers  originating  in  the  intermedio-lateral 
column are of small  calibre and are myelinated;  when grouped, they 
form the white communicating rami. These preganglionic fibers synapse 
with the cell bodies of the postganglionic neurons, which are collected 
into two large ganglionated chains or cords, one on each side of the 
vertebral  column  (paravertebral  ganglia),  and  several  single 
paravertebral ganglia.
Axons of the sympathetic ganglion cells are also of small caliber 
but are unmyelinated. Most of the postganglionic fibers pass via gray 
communicating rami to spinal nerves of T5 to L2, they supply blood 

vessels,  sweat  glands,  and  hair  follicles  and also  form plexuses  that 
supply the heart, bronchi, kidneys, intestines, pancreas, bladder and sex 
organs. The postganglionic fibers of the prevertetral ganglion (located in 
the  posterior  abdomen  rather  than  paravertebrally),  form  the 
hypogastric, splanchnic, and mesenteric plexuses, which innervate the 
glands, smooth muscle and blood vessels of the abdominal and pelvic 
viscera.
There are three cervical (superior, middle and inferior or stellate), 
eleven thoracic, and four to six lumbar sympathetic ganglia. The head 
receives its sympathetic innervation from the eighth cervical and first 
two thoracic cord segments, the fibers of which pass through the inferior 
to the middle and superior cervical ganglia. Postganglionic fibers from 
cells of the superior cervical ganglion follow the internal and external 
carotid arteries and innervate the blood vessels and smooth muscle as 
well as the sweat,  lacrimal and salivary glands of the head. The arm 
receives  its  postganglionic  innervation  from  the  inferior  cervical 
ganglion and uppermost thoracic ganglia (the two are fused to form the 
stellate  ganglion).  The cardiac plexus and other  thoracic  sympathetic 
nerves are derived from the upper thoracic ganglion and the abdominal 
visceral plexuses, from the fifth to the ninth or tenth thoracic ganglia. 
The  lowermost  thoracic  ganglia  have  no  abdominal  visceral 
connections;  the  upper  lumbar  ganglia  supply  the  descending  colon, 
pelvic organs and legs. 
PHYSIOLOGY OF CARDIOVASCULAR REGULATION 15
Cardiovascular regulation is generally mediated through changes 
in vascular resistance and cardiac output by the following
1) ARTERIAL BARORECEPTORS: 
Arterial baroreceptors in the adventitia of the aortic arch and the 
carotid bifurcations are activated by mechanical deformation due to the 
stretching of  the  vessel  wall,  secondary  to  high blood pressure.  The 
increased  baroreceptor  discharge  inhibits  the  tonic  discharge  of  the 
vasoconstrictor  nerves and excites  the vagal  innervation of the heart, 
producing  vasodilation,  venodilation,  a  drop  in  the  blood  pressure, 
bradycardia, and a decrease in cardiac output.                    
2) ARTERIAL CHEMORECEPTORS:
The  aortic  and  carotid  bodies  (Torrance  1968)  are  highly 
vascular,  with  a  flow  of  20  ml/g/mt.  The  chemoreceptors  act  as  a 
emergency system in contrast to baroreceptors which have an ongoing 
regulatory  function.  Stimulation  of  these  leads  to  bradycardia, 
vasoconstriction  in  the  major  vascular  beds  and  an  increase  in  the 
arterial pressure.
3) CARDIAC RECEPTORS:
Cardiac receptors are present in the coronary vessels and within 
each of the four chambers of the heart.
i) Complex  unencapsulated  endings  located  mainly  at  the 
junctions of the pulmonary veins and the atria.
ii) Atrial stetch receptors: The stretch receptors in the atria are 
of  two  types:  those  that  discharge  primarily  during  atrial 
systole (type A), and those that discharge primarily late in 
diastole (type B). The reflex circulatory adjustment initiated 
by  increased  discharge  from  these  receptors  include 
vasodilation and a fall in blood pressure. However, heart rate 
is increased rather than reduced. 
iii) Free nerve endings of unmyelinated vagal C fibres which are 
distributed  throughout  the  heart  and  pericardium.These 
receptors  especially  those  located  in  the  ventricles  are 
responsible  for  the  Bezold-Jarisch  reflex,  the  reflex 
bradycardia  and  hypotension  seen  after  the  injection  of 
veratridine derivatives into the heart.
iv) Sympathetic  afferent  fibres  have  a  role  in  myocardial 
ischeamia.  They have an exicitatory action on sympathetic 
efferent discharge, thus eliciting a tachycardia and increasing 
cardiac contractility.
4)    LUNG STRETCH RECEPTORS:
The majority of afferent  fibres running in the vagus arise from 
stretch  receptors  in  the  lung  parenchyma,  which  are  activated  by 
pulmonary inflation (Hering-Bruer reflex). Lung inflation leads to reflex 
vasodilation in the skin, muscle and splanchic beds due to decrease in 
the sympathetic efferent activity.
5) Several interconnected structures located throughout the rostro-
caudal  brain  axis  have  important  role  to  play  in  cardiovascular 
regulation.
Cardio-inhibitory  centre  in  the  medulla  is  responsible  for  the 
tonic  vagal  discharge  and  the  Nucleus  of  Tractus  Solitarius  projects 
directly to the intermediolateral cell column of the spinal cord.
CENTRAL  NEUROTRANSMITTERS  INVOLVED  IN 
CARDIOVASCULAR REGULATION:15
1) Catecholamines – Adrenaline
                                 Noradrenaline
2) Serotonin
3) GABA
4) Peptides: Angiotensin
Opioid peptides
       Substance P 
     Neuropeptide Y
     Vasopressin
    Kinins
Corticotrophin releasing factor
Bombesin
Somatostatin
DIABETIC AUTONOMIC NEUROPATHY 16
Diabetic  autonomic  neuropathy  (DAN)  can  affect  virtually  all 
systems  of  the  body.  The  DANMAN  is  an  unhappy  person  whose 
symptoms are often nonspecific and vary from clinically unimportant 
(eg:pupillary  abnormalities)  to  great  disability  (eg:Postural 
hypotension). DAN, a subtype of the peripheral polyneuropathies that 
accompany diabetes, can involve the entire autonomic nervous system. 
DAN is  a  serious and common complication  of  diabetes.  Despite  its 
relationship  to  an  increased  risk  of  cardiovascular  mortality  and  its 
association with multiple systems and impairment, the significance of 
DAN has  not  been  fully  appreciated.  DAN may  be  either  clinically 
evident or subclinical. It is manifested by dysfunction of one or more 
organ systems (cardiovascular, gastrointestinal, genitourinary, ocular).17
Subclinical  autonomic  dysfunction  can  occur  within  a  year  of 
diagnosis in type 2 diabetics and within 2 years in type 1 diabetics.18,19,20 
Based  even  on  asymptomatic  subjects  with  abnormality  only  in 
autonomic function tests, the overall mortality rate may be as high as 
25% to 45% over 10 years 21
CLASSIFICATION OF DIABETIC NEUROPATHY 1
A) SYMMETRIC NEUROPATHIES
1) Distal symmetric sensorimotor polyneuropathy
2) Autonomic neuropathy
3) Acute painful neuropathy
4) Hyperglycemic neuropathy
5) Treatment-induced neuropathy
6) Symmetric proximal lower extremity neuropathy
B) FOCAL AND MULTIFOCAL NEUROPATHY
1) Cranial neuropathy
2) Thoracoabdominal neuropathy 
3) Focal limb neuropathy
4) Diabetic amyotrophy
DIABETES AND HEART 22
Diabetes involves heart in the following ways
1) Coronary artery disease
2) Small vessel disease
3) Diabetic cardiomyopathy
4) Heart failure
5) Cardiac autonomic neuropathy
NATURAL  HISTORY  OF  CARDIAC  AUTONOMIC 
NEUROPATHY23
Diabetes is a known disease of complications. Over 50% of either 
sex, above 65 years of age, die from disorders of the heart. Although 
cardiac  autonomic  neuropathy  was  first  envisaged  by Eichorst24 way 
back  in  1892  and  more  comprehensively  dealt  with  by  Rundles  in 
1945,25  its impact in clinical cardiology was not generally appreciated 
until emphasized by Wheeler and Watkins26 as well as by Ewing and co-
workers27 in 1973. Since then (1980 onwards), diabetes related cardiac 
disorders have been generally classified as due to
        1) Premature  and  more  extensive  atherosclerotic  coronary 
artery disease
        2) Cardiomyopathy
        3) Cardiac autonomic neuropathy
These play a role in modification of the clinical characters and the 
progress of the major manifestations of ischemic heart disease. 
Autonomic  damage  in  diabetics  is  not  an  ALL  or  NONE 
phenomenon and it is not well established in which order  symptoms 
develop   although  postural  hypotension  and  gastroparesis  occur 
relatively late in the course of disease indicating poor prognosis. There 
is a great variation in the tendency of individuals to develop symptoms 
and it  is  striking that  some patients who have severe abnormality  of 
autonomic function may have no symptoms. Observations are also made 
of the intermittent nature of features such as postural hypotension and 
diarrohea.  Tests  of  autonomic  function  often  remain  normal  during 
many years of diabetes mellitus and it is not uncommon for many long 
standing diabetics to remain free from autonomic symptoms.  Gradual 
detoriation has been observed in some patients whose tests may decline 
from normal to abnormal in five years. A uniform sequence of cardiac 
autonomic  damage  occurs  in  diabetics,  with  early  cardiac 
parasympathetic  and  later  sympathetic  involvement.  It  is  possible  to 
have cardiac parasympathetic damage without sympathetic damage but 
never the vice versa and once damage has occurred it does not reverse.
The  high  mortality  of  diabetics  with  established  autonomic 
symptoms has been well described by Ewing et al (1980). In many of 
these patients,  autonomic problems are associated with other diabetic 
complications .As many as 37% of the patients with diabetes mellitus 
suffer  from at  least  one microvascular  complication  and atleast  13% 
have  more  than  one.  The  occurrence  of  sudden  and  otherwise 
unexplained deaths amongst autonomic neuropathy patients have been 
described by the Edinburgh group, Ewing et  al  (1980) and Page and 
Watkins (1978).28 
PATHOGENESIS OF NEUROPATHY 29,30,31
Diabetic neuropathies have multifactorial mechanisms and varied 
clinical  presentations.  Length  dependent  symmetrical  nerve  damage, 
primarily  affecting  the  small  unmyelinated  fibres  of  sensory  and 
autonomic systems, is  common in both type 1 and type2 diabetes (= 
50%  after  20  yrs  of  diabetes).  The  evolution  of  the  vagal  damage 
indicates that the autonomic neuropathies are also distal,  symmetrical 
and length dependent. Moreover, autonomic neuropathy coincides with 
small-fibre  somatosensory  neuropathy.In  autonomic  neuropathy 
,presence  of  small  fibre  involvement  and  absence  of  small  vessel 
involvement are the hallmark. Unmyelinated C fibres are predominantly 
involved and the quantum of involvement is high probably indicating 
the  irreversibility  of  autonomic  dysfunction.  Prevalence  is  similar  to 
IDDM  and  NIDDM  patients,  suggesting  that  the  metabolic 
consequences of hyperglycemia, rather than the type of diabetes lead to 
autonomic damage.
Microvascular  complications  in  diabetes  have  traditionally 
included  retinopathy,  nephropathy,  and  neuropathy.  In  each  of  these 
complications,  pathologic  changes  and  cellular  changes  are  seen  in 
nonvascular  tissues  at  early stages itself  and cannot be explained by 
circulatory  changes  alone.  Thus  in  retinopathy  and  neuropathy 
dysfunction  of  neurons  develops  in  parallel  with  microvascular 
pathology.
Multiple abnormalities in diabetic states, including the activation 
of protein kinase C, enhanced oxidative stress, formation of advanced 
glycosylation end products in neuronal tissues and altered expression of 
neurotrophic factors  such as nerve growth factor  and IGF-1 all  have 
been  reported  to  be  important  determinants  for  the  pathogenesis  of 
diabetic  neuropathy.  32,33 Vascular  etiology  in  diabetic  neuropathy  is 
supported by multiple abnormalities in the microvasculature, including 
the  deposition  of  AGE  in  the  perineuronal  vascular  wall,  basement 
membrane thickening, endothelial cell  swelling and loss of pericytes, 
reduced  endothelial  nitric  oxide  activity  and  capillary  occlusion  and 
degeneration  of  blood  vessels  supplying  neuronal  tissues.34All  the 
changes  eventually  contribute  to  hyperglycemia  induced  decrease  in 
neurovascular  blood  flow  and  the  subsequent  hypoxia-ischemic 
damage.35
METABOLIC THEORY
i) POLYOL PATHWAY:
Hyperglycemia  leads  to  excess  intracellular  accumulation  of 
glucose.  This  excess  glucose  gets  converted  to  sorbitol  by  enzyme 
aldose reductase. The accumulation of sorbitol has deleterious effects on 
nerve  conduction  velocity  and  also  depletes  the  myoinositol 
content.Inhibition  of  aldose  reductase  has  been  shown  to  prevent 
experimental  cataracts  and  retinopathy.  It  thus  seems  possible  that 
neuropathy and retinopathy are primarily due to activation of the polyol 
pathway.
ii) MYO-INOSITOL METABOLISM:
Hyperglycemia  causes  increased  intracellular  concentrations  of 
glucose, resulting in increased activity of polyol pathway  and inhibits 
myoinositol  uptake.  Decreased  myoinositol  results  in  abnormal 
phosphoinositide  metabolism,  decreased  diacylglycerol  release  and 
therefore decreased protein kinase C activation leading to reduced Na+ 
K+ ATPase. This leads to increased intra axonal sodium accumulation in 
the  paranodal  regions,  axonal  swelling  and  axoglial  dysjunction  ie: 
separation of the terminations of the myelin lamellae from the axon and 
further structural changes. The reduction in electrogenic Na+ K+ ATPase, 
acutely reduces nerve conduction velocity. In addition, altered inositol 
phospholipid metabolism affects  other  membrane bound proteins and 
voltage dependent sodium channels.
iii) ADVANCED GLYCOSYLATION END PRODUCTS: 
In  the  setting  of  prolonged  hyperglycemia,  nonenzymatic 
glycosylation of proteins occurs, which results in structural changes to 
the  components  of  the  extracellular  matrix.  These  structural  changes 
may lead to functional neural and vascular abnormalities. AGE also may 
quench  nitric  oxide,  thereby  attenuating  endothelium  mediated 
vasodilatation.
iv) PROTEINKINASE C ACTIVATION:  
Hyperglycemia  leads  to  increased  synthesis  of  diacylglycerol, 
which leads to activation of protein kinase C .It may also be activated 
by  oxidative  stress  and  AGE  products.  Protein  kinase  C  activation 
causes increased vascular permeability, impaired nitric oxide synthesis, 
and changes in blood flow. It may also contribute to reduced Na+ K+ 
ATPase activity.
v) OXIDATIVE STRESS36
It is well recognized that reactive oxygen species (ROS) may be 
important  mediators  of  diabetes  and  its  macro  and  microvascular 
complications. In fact, oxidative stress has been proposed as a unifying 
hypothesis linking various molecular  disorders of type 2 DM. Recent 
studies  implicate  that  hyperglycemia  induced  superoxide  generation 
seems to be the key event in the activation of all other pathways in the 
pathogenesis of diabetic complications. These include increased polyol 
pathway flux, increased AGE products, activation of protein kinase C 
and NFkB, and increased hexosamine pathway flux. DNA damage is an 
obligatory  stimulus  for  the  activation  of  the  nuclear  enzyme  PARP, 
which  in  turn  depletes  intracellular  NAD+,  thus  slowing  the  rate  of 
glycolysis,  electron  transport,  ATP  formation  and  produces  ADP 
ribosylation  of  many  proteins.  These  processes  result  in  acute 
endothelial dysfunction in diabetic blood vessels that contributes to the 
development of diabetic complications. 
vi) NEUROTROPHIC FACTORS:
Nerve  growth  factor  (NGF),  the  prototypical  growth  factor,  is 
necessary for the growth maintenance and survival of the sympathetic 
and small sensory nerve fibres. NGF also regulates the expression of the 
neuropeptides, substance P and calcium gene-related peptides in dorsal 
root  ganglion  sensory  neurons  and  sympathetic  nerves.  There  is 
evidence that failure of neurotrophic support is in part responsible for 
the pathogenesis of diabetic polyneuropathy.
VASCULAR THEORY:
Hypoxia, which occurs due to decreased endoneural blood flow is 
sufficient  to  produce  nerve  dysfunction.  The  normal  vascular  auto 
regulation  is  said  to  be  lost.  The  decreased  blood  flow  leads  to 
endoneural hypoxia and also decreases the Na+ K+ ATPase. This reduces 
the nerve conduction velocity by decreasing axonal transport and leads 
on to axonal atrophy.
THOUGH  VASCULAR  AND  METABOLIC  HYPOTHESIS  FOR 
THE PATHOGENESIS OF DIABETIC NEUROPATHY HAS BEEN 
POSTULATED,  THE  DIVISION  IS  ARTIFICIAL.MORE  OFTEN 
THERE  IS  OVERLAY  OF  METABOLIC  AND  VASCULAR 
EVENTS.
PATHOLOGY1
The  pathologic  basis  of  diabetic  autonomic  neuropathy  is  not 
completely  understood.  A  number  of  investigators  have  identified 
abnormalities  in paravertebral  sympathetic  ganglia,  including neurons 
distended  by  lipid  rich  material,  vacuolar  degeneration  of  neurons 
produced by dilation of endoplasmic reticulum, and mononuclear cell 
infiltration of autonomic nerve bundles and ganglia. Loss of myelinated 
nerve fibres has  been described in  sympathetic  communicating  rami, 
vagus nerves, splanchic nerves and nerves to the bladder wall.
CLINICAL  PRESENTATION  OF  CARDIAC  AUTONOMIC 
NEUROPATHY
CARDIAC DENERVATION
 Cardiac dysautonomia refers to autonomic dysfunction of heart. 
It  appears to be the most  frequent  complication of diabetes mellitus. 
There are two terms 
1) Autonomic neuropathy
Refers to combined clinical and objective evidence of autonomic 
involvement
2) Autonomic dysfunction
Refers to abnormal cardiovascular tests in the absence of clinical 
symptoms.
Cardiac autonomic neuropathy occurs in about 17% of patients 
with type 1 DM and 22% of those with type 2 DM. An additional 9% of 
type 1 patients and 12% of type 2 patients have borderline dysfunction.37 
Using cardiovascular reflex tests, the prevalence is reported to be 17 % 
to 40%38,39.The prevalence is associated with both duration 40 of diabetes 
and with age and is equal to or higher in type 2 than in type 1 DM. 41 
Diabetic autonomic  neuropathy is usually  accompanied by peripheral 
neuropathic disturbances.22  Estimates  of  the mortality  associated  with 
Cardiac autonomic neuropathy range from 27% to 56% over 5 to 10 
years.1
Autonomic  nerves  provide  the  heart  with  very  fine  control 
mechanism, variations in parasympathetic (vagal) tone very rapidly alter 
heart rate on a beat to beat basis while stimulation of sympathetic tone 
has a more gradual cardioaccelerator effect. Both parasympathetic and 
sympathetic denervation occur in diabetics, parasympathetic impairment 
occurs first,  followed by sympathetic  denervation.  Loss  of  heart  rate 
variation both at rest and during deep breathing and loss of immediate 
heart rate acceleration and overshoot on standing are also result of vagal 
impairment  and  commonly  occur  in  diabetic  cardiac  autonomic 
neuropathy.
Sympathetic denervation occurs later in the disease and always 
follows vagal damage. Complete  sympathetic  denervation is rare, but 
occasionally the heart is totally denervated of its parasympathetic and 
sympathetic nerve supply.42    
Ewing  et  al  found  that  40  %  of  all  diabetics  have  some 
impairment of cardiac autonomic neuropathy. Mackay et al found that 7 
% of diabetics without peripheral neuropathy and 80 % of those with 
peripheral  neuropathy  have  autonomic  dysfunction.  For  unknown 
reason the incidence is said to be much higher in non-caucasians (70-
80%).
The  onset  of  symptoms  is  usually  insidious  with  no  typical 
pattern in the early stages.  Autonomic damage may be asymptomatic 
and thus be detected incidentally, even if asymptomatic they are mostly 
unnoticed  due  to  the  vagueness  of  early  symptoms.  The  autonomic 
nervous  system,  through  the  sympathetic  and  parasympathetic 
pathways, supplies and influences every organ in the body. It closely 
integrates vital processes such as heart rate, blood pressure, myocardial 
contractility and body temperature and as a consequence plays a pivotal 
role in the regulation of the cardiovascular system. Cardiac autonomic 
neuropathy (CAN) represents a serious complication.
The features of cardiac autonomic neuropathy include
                1) RESTING TACHYCARDIA
                2) EXERCISE INTOLERANCE
                3) POSTURAL HYPOTENSION
                4) FIXED HEART RATE
                5) PAINLESS (OR) SILENT MYOCARDIAL INFARCTION
Although  insidious  in  onset,  autonomic  neuropathy  may  be 
associated with substantial  morbidity. CAN is associated with a high 
risk of unexpected and sudden death. There is increased susceptibility to 
fatal ventricular arrythmias. Any diabetic with CAN is at a considerable 
anaesthetic risk.
EXERCISE INTOLERANCE:
Exercise  intolerance  is  due  to  impaired  sympathetic  and 
parasympathetic  responses  that  normally  augment  cardiac  output  and 
redirect peripheral blood flow to skeletal muscles. Diminished cardiac 
acceleration may also play a role.
RESTING TACHYCARDIA:
 It is an early sign. There are several reports of resting heart rate in 
excess of 95 bpm in diabetics with autonomic damage and sometimes 
more rapid rates upto 130 bpm. The tachycardia may be followed by a 
decrease  in  heart  rate  and  ultimately,  a  fixed  heart  rate  due  to  the 
progressive dysfunction of the cardiac sympathetic nervous system.
POSTURAL HYPOTENSION:
The most incapacitating manifestation of autonomic failure, is a 
common feature of  diabetic  cardiovascular  neuropathy.  It  is  a fall  in 
systolic  blood pressure  of  more  than 30 mmHg upon standing from 
supine position.
In  1945,RUNDLES43  first  linked  postural  hypotension  with 
autonomic  neuropathy  in  diabetes.  Maintenance  of  BP  on  standing 
depends on afferent  impulses  from baroreceptors  in the carotid sinus 
and on efferent sympathetic impulses to the heart and blood vessels. In 
normal people there is a 20% fall in cardiac output on standing, (about 
700 cc of blood). Compensatory mechanisms prevent a fall in BP. If one 
or  more  of  the  pathways  in  this  system  are  impaired,  postural 
hypotension occurs. Postural hypotension is an essential complication of 
diabetic autonomic neuropathy (MARTIN 1953) and is chiefly due to 
efferent sympathetic vasomotor denervation (MOORHOUSE et al 1966, 
BENNETT et al 1975). It occurs in patients with advanced neuropathy 
as a sympathetic defect is usually a late feature.
Failure of cardiac acceleration and reduced cardiac output both 
contribute to the problem. Noradrenaline levels are generally reduced in 
diabetics with postural hypotension. Insulin is known to have its own 
effects.44 It  causes  a  reduction  in  plasma  volume,  an  increase  of 
peripheral blood flow from vasodilation and an increase in heart rate. In 
patients with autonomic neuropathy, insulin may cause an exacerbation 
of postural hypotension.    
Though  many  patients  may  be  asympotamatic  inspite  of 
significant  postural  hypotension,  typically  patients  complain  of  light 
headedness,  weakness,  visual  changes  and  palpitations.  These 
symptoms can be mistaken for hypoglycemia. Both hypotension and it 
symptoms  fluctuate  spontaneously  to  a  remarkable  degree  and  may 
persist for many years without necessarily deteriating.45
FIXED HEART RATE:
Heart rate show less diurnal variation with increasing autonomic 
damage. The loss of the normal cardiac slowing at night results from 
vagal damage. With severe damage there is loss of minute to minute and 
second to second variation in  heart  rate,  resulting in  relatively  fixed 
heart rate.  
PAINLESS (OR) SILENT MYOCARDIAL INFARCTION:
Autonomic  neuropathy  reduces  the  perception  of  cardiac 
ischaemic pain. Diabetic patients admitted to hospital with myocardial 
infarction  have  been  reported  to  suffer  from  less  intense  pain  than 
nondiabetic patients. Margolis et al reviewed the ECG of all patients in 
Framingham heart study and found that 23% of myocardial infarction 
were silent.
ASSESSMENT  OF  CARDIOVASCULAR  AUTONOMIC 
DYSFUNCTION 11,41,46,47- 51
Objective measurement of autonomic nerve damage is based on 
parasympathetic  and  sympathetic  cardiovascular  reflexes.  The 
abnormalities in cardiovascular reflexes is assumed to reflect autonomic 
damage elsewhere and the evidence suggests that it does. This is aided 
by screening tests, although indirect, are widely used because they are 
simple, non- invasive, reproducible and give a clear distinction between 
normal and abnormal. Symptoms such as lack of sweating on the feet 
and impotence may antedate abnormal cardiovascular tests.
TESTS FOR PARASYMPATHETIC FUNCTION
1) HEART  RATE RESPONSE TO DEEP BREATHING
2) HEART RATE RESPONSE TO STANDING
3) HEART RATE RESPONSE TO VALSALVA MANOEUVRE
TESTS FOR SYMPATHETIC FUNCTION
     1) BLOOD PRESSURE  RESPONSE TO STANDING
     2)  BLOOD PRESSURE RESPONSE TO SUSTAINED HAND 
GRIP
HEART RATE RESPONSE TO DEEP BREATHING:
This test is a sensitive and specific index of autonomic function. 
It is the best noninvasive test to assess cardiac vagal innervation. The 
normal  acceleration and deceleration  of  the heart  rate  during normal 
respiration  (sinus  arrthymia)  is  reduced  early  in  the  course  due  to 
cardiac vagal involvement.Sinus arrthymia is very commonly absent in 
diabetics with autonomic neuropathy, and is the most easy bedside test. 
The patient breathes deeply and evenly at the rate of six breaths 
per minute ie: five seconds each for inspiration and five seconds for 
expiration, a rate, which produces maximum variation in heart rate.
The heart rate is measured by an instantaneous heart rate monitor 
or more simply from an ECG.RESULT: Maximum and minimum heart 
rates during each breathing cycles are measured and the mean of the 
differences during three successive cycles taken to give the maximum – 
minimum heart rate expressed as E/I ratio.
HEART RATE RESPONSE TO STANDING:
This  test  evaluates  the  cardiovascular  response  elicited  by  a 
change from a horizontal to vertical position. The subject is asked to 
stand abruptly from a supine position once the BP and HR are stable 
after atleast a 10-min period of quite supine rest. In healthy subjects, 
there is a characteristic and rapid increase in heart rate in response to 
standing that is maximal at approximately the 15th beat after standing 
and followed by slowing, maximal after the 30th beat. This is expressed 
as the 30:15 ratio, the ratio of the longest R-R interval around the 30th 
beat to the shortest around the 15th beat.
In patients with diabetic autonomic neuropathy, there is only a 
gradual increase in heart rate. The changes in heart rate are largely due 
to the withdrawal of parasympathetic drive.
HEART RATE RESPONSE TO VALSALVA MANOEUVRE:
In  the standard  valsalva  manoeuvre,  the  patient  exhales  into a 
manometer  or  against  a  closed  glottis  for  10  to  15  sec,  creating  a 
markedly positive intrathoracic pressure. 
          The response to performance of the valsalva manoeuvre has four 
phases  and  in  healthy  individuals  can  be  observed  as  follows.  The 
phases of valsalva manoeuvre  were defined by (Hamilton et al., 1936)
PHASE 1:  Transient rise in blood pressure and a fall in heart rate 
due to compression of the aorta   and propulsion of the blood into 
the peripheral circulation.
PHASE  2:   Early  fall  in  blood  pressure  with  a  subsequent 
recovery of blood pressure later in the phase. The blood pressure 
changes  are  accompanied  by  an  reflex  increase  in  heart  rate. 
There is a fall  in cardiac output due to impaired venous return 
causing  compensatory  cardiac  acceleration,  increased  muscle 
sympathetic activity and peripheral resistance.
PHASE 3: Abrupt, transient decrease in blood pressure and rise 
of  heart rate with cessation of straining.
PHASE  4:  Blood  pressure  increases  above  the  baseline  value 
(overshoot)  because  of  residual  vasoconstriction  and  restored 
normal venous return and cardiac output and reflex bradycardia is 
seen.
The  responses  are  mediated  through  alternating  activation  of 
parasympathetic  and  sympathetic  nerve  fibres.  In  patients  with 
autonomic  damage  from diabetes,  the  reflex  pathways  are  damaged. 
This is seen as a blunted heart rate response and sometimes as a lower 
than normal decline in blood pressure during strain, followed by a slow 
recovery after release.
The  Valsalva  ratio  is  determined  from  the  ECG  tracings  by 
calculating the ratio of the longest R – R interval after the manoeuvre to 
the shortest  R-R interval  during the  manoeuvre.  The ratio  is  usually 
expressed as the mean ratio of three successive tests.
SYSTOLIC BLOOD PRESSURE RESPONSE TO STANDING:
The most frequently performed cardiovascular test for assessing 
sympathetic function is the blood pressure response to postural change. 
Blood  pressure  normally  changes  only  slightly  on  standing  from  a 
supine position. In healthy subjects,  there is an immediate pooling of 
blood in the dependent circulation resulting in a fall in blood pressure 
that  is  rapidly  corrected  by  baroreflex  mediated  peripheral 
vasoconstriction  and  tachycardia.  In  normal  individuals,  the  systolic 
blood pressure falls by       ≤  10 mmHg in 30 sec. In diabetic patients 
with  autonomic  neuropathy,  baroreflex  compensation  is  impaired. 
Several  recordings  of  BP  and  HR  responses  within  first  5  minutes 
(usually  within the first  2  minute)  are sufficient  to  detect  orthostatic 
hypotension and whether the heart rate response is normal. Recently , 
the Consensus Committee of the American Autonomic Society and the 
American  Academy  of  Neurology  (1996)  has  defined  orthostatic 
hypotension as fall in systolic BP of  ≥  20 mmHg or diastolic BP of  ≥  
10 mmHg within 3 minutes of standing.
DIASTOLIC  BLOOD  PRESSURE  RESPONSE  TO  SUSTAINED 
HANDGRIP:
Sustained  (isometric)  muscle  contraction  as  measured  by  a 
handgrip  dynamometer  causes  a  rise  in  systolic  and  diastolic  blood 
pressure  and  heart  rate.  The  efferent  fibres  innervate  the  heart  and 
muscle, resulting in increased cardiac output, blood pressure and heart 
rate.  Blood  pressure  is  measured  with  30%  of  maximum  voluntary 
contraction using a hand grip dynamometer for 5 minutes. The normal 
response is a rise of diastolic blood pressure of > 16mmHg, whereas a 
response of < 10mmHg is considered abnormal. Patients with DAN are 
more likely to exhibit only a small increase in diastolic blood pressure.
Values in tests of cardiovascular autonomic function
TESTS REFLECTING 
PARASYMPATHETIC 
FUNCTION
Normal Borderline Abnormal
Heart  rate  variation  during 
deep breathing (E/I) ratio
> 1.1 - ≤  1.1
Heart  rate  response  to 
standing (30:15) ratio
≥  1.04 1.01- 1.03 ≤  1.00
Heart  rate  response  to 
valsalva manoeuvre 
≥  1.21 1.11- 1.20 ≤  1.10
TESTS REFLECTING 
SYMPATHETIC 
FUNCTION
Blood pressure  response  to 
standing
≤  10 mmHg 11-29 mmHg ≥  30 
mmHg
Blood pressure  response  to 
sustained hand grip
≥  16mmHg 11-15 mmHg ≤  10 
mmHg
The classification of the tests as parasympathetic or sympathetic, 
though useful, is not physiologically precise because the cardiovascular 
reflexes are complex and involve both sympathetic and parasympathetic 
fibres to a great or lesser extent. Therefore, the tests are better defined as 
normal, early, definite and severe.
EWINGS AND CLARKES Classification according to severity:
1) Normal – All five tests are normal or one borderline.
2) Early involvement- One of the three heart rate tests are abnormal 
or two borderline
3) Definite involvement – Two or more of the heart rate tests are 
abnormal
4) Severe involvement  – Two or  more  of  the heart  rate  tests  are 
abnormal plus one or both blood pressure tests abnormal, or both 
borderline
5) Atypical  pattern  –  Any  other  combination  of  abnormal  tests. 
In Ewings experience only about 6% of the patients tested were 
atypical.
An alternative to this classification is to give each individual a 
score of 0, 1 or 2 depending on whether they are respectively normal, 
borderline or  abnormal.  An overall  autonomic test  score of 0-10 can 
then be used.
NORMAL: 0 and 1
     EARLY: 2, 3 and 4
     DEFINITE: 4, 5, 6 and 7
     SEVERE: 7, 8, 9 and 10
Lloyd-Mostyn and Watkins 42 found that cardiac parasympathetic 
function could be impaired but not the reverse, while Wieling et al52 
concluded  that  sympathetic  lesions  occurred  only  in  diabetics  with 
longstanding disease with extensive cardiac vagal damage.
The early  parasympathetic  involvement  may  be  more  apparent 
than real because heart rate based tests are much more sensitive than BP 
based  tests.  However  the  detailed  physiological  studies  show 
unequivocally  that  parasympathetic  fibres  are  damaged  earlier  than 
sympathetic fibres possibily because they are longer and therefore more 
liable to damage, as also suggested by computer stimulated models of 
random nerve damage in which longer fibres were affected first.
MANAGEMENT
MANAGEMENT OF PATHOGENIC MECHANISMS:
STRICT GLYCEMIC CONTROL:
Management of diabetic neuropathy begins with the treatment of 
hyperglycemia. Strict glycemic control has shown to decrease the risk of 
developing  neuropathy  and  to  slow  the  progression  of  established 
neuropathy. The Diabetes Control and Complications Trial (DCCT) in 
1993 unquestionably established the necessity of meticulous control of 
hyperglycemia.
TREATMENT OF METABOLIC ABNORMALITIES:
ALDOSE REDUCTASE INHIBITORS
Aldose reductase inhibitors reduce the flux of glucose through the 
polyol pathway, inhibiting tissue accumulation of sorbitol and fructose 
and preventing reduction of redox potentials.
Alrestatin
Sorbinil
Tolrestat
Zenarestat
Trials with these class of agents are still in progress.
MYOINOSITOL:
There are several studies suggesting that myoinositol supplements 
in  the  diet  improves  neuropathy,  but  the  treatment  may  have  to  be 
prolonged for atleast six months for significant results to be achieved.
TRENDS FOR THE FUTURE
INHIBITORS OF GLYCATION
AMINOGUANIDINE – an inhibitor of non-enzymatic glycation 
is  under  trial.  They  have  shown  some  beneficial  effects.  Its  precise 
mechanism of action remains obscure. 
GAMMA LINOLEIC ACID
Linoleic  acid,  an essential  fatty  acid is  metabolized to  gamma 
linolenic  acid,  which  serves  as  an  important  constituent  of  neuronal 
membrane  phospholipids,  and  also  serves  as  a  substrate  for 
prostaglandin  E  formation  which  is  vital  for  preserving  nerve  blood 
flow.
ALPHA LIPOIC ACID
The  effects  of  the  alpha  lipoic  acid  were  studied.  This  is  a 
derivative of octanoic acid and is shown to be effective in ameliorating 
both somatic and autonomic neuropathy in diabetes.
NEUROTROPHINS
NGF  is  the  most  widely  studied  neurotrophin.  Nerve  growth 
factor  binds  to  high  and  low  affinity  nerve  growth  factor  receptors 
present  on  small,  unmyelinated  fibres  of  the  sensory  neurons  of  the 
peripheral  nervous system,  on sympathetic  neurons in  the autonomic 
nervous system, and in the regions of the central nervous system. This 
therapy  is  under  trial  and  is  directed  towards  regeneration  of  the 
damaged nerves.
PROTEIN KINASE C INHIBITION
Trials are currently under progress using specific protein kinase c 
inhibitor ROBOXISTAURIN. This has found to reduce the symptoms 
and signs of peripheral neuropathy.  
MANAGEMENT AIMED AT SYMPTOMS
CARDIOVASCULAR53
The resting tachycardia and heart  rate  variation do not  require 
treatment.
Postural hypotension can be managed as follows:
1) Stop  any  drugs  which  may  exacerbate  hypotension 
eg: hypotensive agents, diuretics, tricyclic antidepressants 
and nitrates.
2) Postural  changes  of  blood pressure  on getting  up in  the 
morning can be prevented by sleeping in as nearly vertical 
position as possible.
3) Antigravity suits as worn by astronauts can completely cure 
postural hypotension but are hardly practical.
4) Full length elastic stockings which must come up to and 
preferably above the waist may be effective.
5) DRUGS : 
a) 9-alpha-fluorohydrocortisone  (fludrocortisone)  a 
potent  mineralocorticoid  promotes  renal  sodium 
reabsorption and increases sensitivity of arterioles to 
norepinephrine. Dose 0.1 mg once or twice per day
b) Midodrine is an alpha 1 agonist, started at a dose of 
2.5 mg per day and increased to 30 mg per day in 2 
to 3 divided doses.
c) Other  sympathomimetics  such  as  ephedrine, 
pseudoephedrine,  phenylephrine,  phenylpropan-
olamine   have been used.
NUTRITIONAL SUPPLEMENTS
ANTIOXIDANTS
Antioxidants play a pivotal role in preventing the progression of 
diabetic  neuropathy.  Their  role  in  autonomic  neuropathy is  validated 
through many trials; eg. Ziegler et al proved the efficacy of antioxidants 
in CAN. The following agents are recommended.
Vitamin A
Vitamin C
Vitamin E
Selenium
N Acetyl cysteine
Gingko Biloba Extract
OTHERS
Chromium,  Biotin,  Niacin,  Inositol,  Taurine,  Magnesium  have 
also been tried and is recommended for prevention of DAN.
MATERIALS AND METHODS
Cardiac Autonomic Neuropathy System Analyser model CANS 
504  is  an  important  tool  to  measure  and  diagnose  Autonomic 
dysfunction using ECG R-R interval  and automatic  BP measurement 
with various manoeuvre.
FEATURES:
1. Analyses  both  sympathetic  and  parasympathetic 
autonomic function
2. Simple test procedures
3. Upgradable to future development
4. Two page comprehensive report for easy interpretation
5. Accurate and repeatable values
CONTROLS:
ECG INPUT:
A 3 lead ECG patient cable is connected to this connector. The 
colour  coding  of  the  patient  with  lead  details  are  indicated  on  the 
respective leads. Plug the cable and tighten the screws provided in the 
plug.
QRS: A red LED blinks for every QRS detected.
BP CUFF:
An automatic BP measurement cuff is to be connected to the unit 
for  measuring the BP.  The cuff  has to be connected correctly to the 
patient. The arrow mark on the cuff should be placed on or near the 
brachial artery of the patient.
VALSALVA:  
This  control  is  used  for  detecting  the  ECG  response  due  to 
valsalva manoeuvre. A pressure sensor is used by the unit to detect the 
blowing pressure of the patient. The patient is asked to blow through the 
mouthpiece of the control and as he /she blows the pressure, value in 
mmHg is varied and displayed on the computer. The patient has to blow 
and maintain 40mmHg of pressure for 20 sec. If the patient goes less 
than the prescribed value the test is terminated automatically. Again the 
patient  is  asked  to  perform the  test  without  going  below the  value. 
However we cannot expect every patient to blow and hold the value for 
20 sec. A begin and end mark is displayed during the one minute ECG 
performed.
HAND GRIP: 
This spring loaded accessory is used for finding out the sustained 
handgrip function. The patient is asked to apply the maximum grip and 
the system measures it and finds the 30% of the maximum grip of the 
patient. Then the patient has to hold the grip for the 30% value indicated 
for 5 minutes before the BP measurement is enabled.
MATERIALS:
STUDY GROUP:
We  undertook  the  study  in  a  randomly  selected  40  Type  2 
diabetic  patients  attending  the  out  patient  department  of  Ambedkar 
Institute of Diabetology, KMC, Chennai.   
Period of Study: April 2007 - August 2007.
These subjects were selected after scrutinizing them for exclusion 
criteria.
METHODS:
        All  patients  were subjected  for  thorough physical  examination. 
Blood  samples  were  drawn  and  subjected  to  estimation  of  plasma 
glucose and renal function tests.
EXCLUSION CRITERIA:
1. Symptomatic coronary artery disease.
2. Drug  intake  including  antidepressants,  antihistaminics, 
diuretics,  aspirin,  anticholinergics,  β  agonists  and  β 
blocker.
3. End organ failure.
4. Other concomitant diseases.
5. Exercise, smoking and caffeine intake.
6. Chronic obstructive pulmonary disease.
7. Treatment for Parkinsonism.
8. Hypothyrodism.
Autonomic dysfunction was assessed using following parameters
TESTS FOR PARASYMPATHETIC FUNCTION
1) Heart rate response to deep breathing
2) Heart rate response to standing
3) Heart rate response to valsalva manoeuvre
TESTS FOR SYMPATHETIC FUNCTION:
1) Systolic blood pressure response to standing
2)  Diastolic blood pressure response to sustained handgrip
After  connecting  all  the  accessories  to  the  unit,  prepare  the 
patient. The patient is explained of all the procedures in detail .After 
instructing the patient, attach the ECG electrodes. The patient should 
not touch the metal part. Ensure proper earth before starting the test.
HEART RATE RESPONSE TO DEEP BREATHING:
Select  the  resting  ECG  option.  The  ECG  waveform  will  be 
displayed on the screen and continue to run for a minute. After finishing 
resting  ECG  select  deep  breathing  test.  The  patient  has  to  inhale 
strongly for 5 seconds and exhale for 5 seconds. This test is done for a 
minute and during this time the patient would have done 6 cycles of 
breathing. Patient should be in supine position.
HEART RATE RESPONSE TO STANDING:
The patient after a rest of 4 to 5 minutes, one minute supine ECG 
is taken. Then the patient is asked to stand unaided on a nonconducting 
plastic floor mat and the ECG is recorded in the standing position.
HEART RATE RESPONSE TO VALSALVA MANOEUVRE:
The patient should be in supine position. Ask the patient to hold 
the valsalva probe tightly and keep the mouthpiece in the mouth tightly. 
The patient should blow hard and the value will increase. Normally the 
value will be indicated as green colour and when they reach 40 mmHg 
or more it turns into green in colour. Once they reach the range they 
should not reduce the blow since the test will be terminated immediately 
after the pressure is less than 40 mmHg. The patient should blow and 
maintain this value for 20 sec.
SYSTOLIC BLOOD PRESSURE RESPONSE TO STANDING:
Select  BP  SUPINE,  automatically  the  BP  cuff  is  inflated  to 
measure the systolic and diastolic BP. Then the patient is asked to stand 
immediately.  Select  BP  STANDING  for  measuring  the  BP.  This 
procedure takes about 40 sec. BP is taken automatically 60 sec after the 
first BP measurement.
DIASTOLIC  BLOOD  PRESSURE  RESPONSE  TO  SUSTAINED 
HANDGRIP:
Ask the patient to get the maximum grip from the grip meter and 
the value is displayed on the system. After getting the maximum grip it 
detects the 30% of the grip value and it is displayed. The patient has to 
hold this 30% value for  5 minutes continuously and at  the end of  5 
minutes, BP after grip is applied and BP value is taken.
The values for various tests are interpreted and print out of the 
waveforms is taken.
DETECTION OF PERIPHERAL NEUROPATHY:
         10 g monofilament was used to check the presence or absence of 
sensation in the foot. Vibration perception threshold (VPT) was checked 
in the foot using a biothesiometer (6 sites were examined –great toe, 1st, 
3rd, 5th metatarsal heads, instep, heel).
Peripheral  neuropathy if  present  was graded as mild,  moderate 
and severe. (VPT 11-15 V mild, 16 – 25 V moderate, > 25 V  severe)
DETECTION OF NEPHROPATHY:
History of diabetic nephropathy was taken. Early morning urine 
sample was analysed for albumin using dip stick method. Two samples 
were analysed. Urine for microscopic examination was done to exclude 
active urinary sediments. Patients having urine albumin positive for 2 
sample  using  dipstick  method,  were  considered  to  have  diabetic 
nephropathy.
DETECTION OF RETINOPATHY:
Ocular  fundus  was  examined  by  ophthalmologist  after  proper 
dilatation of the pupil using mydriatic.  Direct opthalmoscopy method 
was used. Levels of diabetic retinopathy were noted.
Statistical Analysis
The statistical methods used for analysis were
1. Two sample `t' test
2. Chi-Square test
3. Fisher exact 2 tailed test.
RESULTS AND ANALYSIS
Total No of subjects included in the study = 40
Males = 25 (62%)
          Females = 15 (38%)
Mean age of individuals studied = 46.8 yrs
DURATION OF TYPE 2 
DM
MALE FEMALE TOTAL
0 -5 YRS 21 9 30
6 -10 YRS 3 4 7
> 10 YRS 1 2 3
25 15 40
Mean duration of diabetes = 6.03 yrs
No of cases of diabetes less than 5 yrs = 30
Males = 21
Females = 9
No of cases of diabetes between 6 to 10 yrs = 7
Males = 3
Females = 4
No of cases of diabetes greater than 10 yrs = 3
Males = 1
Females = 2
12 out of the 40 cases (30%) had postural giddiness.
8 out of the 40 patients were found to be smokers.
5 out of the 40 patients were found to be alcoholics.
Resting tachycardia of 100/mt and above were seen in 5 out of the 
40 patients (12%).
Cardiac Autonomic Function Tests were found to be 
Normal = 14 (35%) Total = 40
Early = 12 (30%) Normal = 14
Definite = 6 (15%) Abnormal = 26
Severe = 4 (10%)
Atypical = 4 (10%)
Heart Rate Variability to Deep Breathing( E/I Ratio )
E/I RATIO
NORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
NORMAL 14 11 25
ABNORMAL 0 15 15
14 26 40
P = 0.000325  SIGNIFICANT
Out of the 26 patients with abnormal cardiac autonomic function 
tests, 15 patients were found to have abnormal E/I ratio i.e 57%. P value 
is significant (P = 0.000325).
Heart Rate Response to Standing (30/15 Ratio)
30/15 
RATIO
NORMAL FOR 
AUTONOMIC 
FUNCTION 
TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION 
TESTS
TOTAL
NORMAL 14 11 25
ABNORMAL 0 15 15
14 26 40
P = 0.000325    SIGNIFICANT
Out of the 26 patients with abnormal cardiac autonomic function 
tests, 15 patients were found to have abnormal 30/15 ratio i.e 57%. P 
value is significant (P = 0.000325).
Valsalva Ratio
VALSALVA 
RATIO
NORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
NORMAL 14 20 34
ABNORMAL 0 6 6
14 26 40
P = 0.051225   NON SIGNIFICANT
Out of the 26 patients with abnormal cardiac autonomic function 
tests, 6 patients were found to have abnormal valsalva ratio i.e 26%.      
P value is non significant (P = 0.051225).
Fall in Systolic BP
FALL IN 
SYSTOLIC 
BP
NORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
NORMAL 14 24 38
ABNORMAL 0 2 2
14 26 40
P = 0.53333 NON SIGNIFICANT
Out of the 26 patients with abnormal cardiac autonomic function 
test, only 2 patients had fall in systolic BP. P value is non significant 
(P = 0.53333).
Increase in Diastolic BP with hand grip
INCREASE IN 
DIASTOLIC 
BP
NORMAL FOR 
AUTONOMIC 
FUNCTION 
TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
NORMAL 14 23 37
ABNORMAL 0 3 3
14 26 40
P = 0.30000    NON SIGNIFICANT
Out of the 26 patients with abnormal cardiac autonomic function 
tests, only 3 patients had increase in diastolic BP with hand grip.     
P value is non significant (P = 0.3000).
Other Microvascular complications
Peripheral Neuropathy
PERIPHERAL 
NEUROPATHY
NORMAL FOR 
AUTONOMIC 
FUNCTION 
TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
YES 1 21 22
NO 13 5 18
14 26 40
P = 0.000008  SIGNIFICANT
Total No of Cases with Peripheral Neuropathy = 22
Mild = 11
Moderate = 11
Abnormal cardiac autonomic neuropathy is seen in 21 of these 
patients  with  Peripheral  Neuropathy  and  1  patient  had  no  cardiac 
autonomic dysfunction.
5  patients  with  CAN  did  not  have  peripheral  neuropathy. 
Significant  correlation  was  found  between  CAN  and  peripheral 
neuropathy with P value of 0.000008.
Retinopathy
RETINOPATHY NORMAL FOR 
AUTONOMIC 
FUNCTION 
TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
YES 1 9 10
NO 13 17 30
14 26 40
P = 0.1157 NON SIGNIFICANT
Total No of Cases with fundus abnormality = 10
Out  of  the  10  patients,  9  patients  had  abnormal  CAN  and  1 
patient had normal cardiac autonomic function. Out of the 26 patients 
with  abnormal  CAN  only  9  patients  had  fundus  involvement.  Their 
correlation was statistically non significant with P = 0.1157.
Nephropathy
NEPHROPATHY NORMAL FOR 
AUTONOMIC 
FUNCTION 
TESTS
ABNORMAL FOR 
AUTONOMIC 
FUNCTION TESTS
TOTAL
YES 1 10 11
NO 13 16 29
14 26 40
P = O.O613   NON SIGNIFICANT
Total No of cases with nephropathy = 11
Out  of  the  11  patients,  10  patients  had abnormal  CAN and  1 
patient had normal cardiac autonomic function. Out of the 26 patients 
with abnormal  CAN only 10 patients  had abnormal  kidney function. 
Others are found to be normal. Their correlation was statistically non 
significant with P = 0.0613.
Correlation between Microvascular Complications
1. Peripheral  Neuropathy,  Retinopathy,  Nephropathy  were 
associated with CAN in 3 patients.
2. Two microvascular complications (either of the 3) were found 
associated with CAN in 10 patients.
3. At  least  one  microvascular  complication  was  found  to  be 
associated with   CAN in 9 patients.
4. 3  patients  with  CAN  had  no  other  microvascular 
complications.
DISCUSSION
Cardiac Autonomic Neuropathy is a easily detectable dysfunction 
among other involved systems of the body.
Symptoms attributable to CAN was obtained in about 12 patients 
(30%).  It  was  mainly  postural  giddiness.  Rundles  (1945)43 study 
showed a prevalence of 6%  and Balachander & Chandrasekar study 
(1984)54 showed  a  prevalence  of  46%.  Present  study  showed  a 
prevalence of about 30%.
Cardiac Autonomic Function Tests
The results of autonomic function tests in this study are compared 
to that by EWING & CLARKE (1985)55 as follows
     Category EWING & CLARKE Present Study
     Normal 39% 25%
     Early 15% 30%
     Definite 18% 15%
     Severe 22% 10%
    Atypical 6% 10%
However  the  study  by  Ewing  &  Clarke  was  on  a  Caucasian 
population of  543 diabetics  in contrast  to this  study on south Indian 
population of 40 Type 2 diabetics. So the variations observed may be 
due to either a small sample size or the Non-caucasian population which 
has been studied.
Correlation between CAN and 
1. Duration of DM
In the present study, it was found that with increasing duration of 
DM, the incidence of autonomic dysfunction increases. 
CAN NO MEAN OF 
DURATION 
OF DM
95% CONFIDENCE 
INTERVAL
LCL OF 
MEAN
UCL OF 
MEAN
NORMAL  FOR 
AUTONOMIC 
FUCNTION TEST
14 1.75 1.286569 2.21343
ABNORMAL 
FOR 
AUTONOMIC 
FUCNTION TEST
26 6.038462 4.330617 7.746306
It is found that as the duration of diabetes increases over 6 yrs, 
they  are  more  prone  to  develop  CAN.  The  Diabetes  Control  and 
Complications Trial(DCCT)46 found that 1.6% of patients with a 5 years 
history  of  diabetes  had  lack  of  heart  rate  variability  during  deep 
breathing.  The rate  rose to  6.2% of those  with a  5  years  to  9 years 
history of diabetes and to 12% in those who had the disease for more 
than 9 years.
2. AGE OF THE PATIENT:
CAN NO
MEAN 
OF AGE
95% CONFIDENCE 
INTERVAL
LCL OF 
MEAN
UCL OF 
MEAN
NORMAL FOR 
AUTONOMIC FUNCTION 
TEST
14 39.35714 34.41823 44.29605
ABNORMAL FOR 
AUTONOMIC FUNCTION 
TEST
26 50.88462 47.04034 54.72889
P = 0.000539  SIGNIFICANT
A significant correlation was seen between the increasing age of 
the patient and development of cardiac autonomic neuropathy. 
3. Obesity
We  found  no  significant  difference  in  the  BMI/WHR  among 
those  patients  with  normal  autonomic  function  tests  compared  to 
abnormal  autonomic  function  tests.  P  value  is  found  to  be  non 
significant. 
CAN NO MEAN 
OF BMI
S.D S.E
NORMAL FOR AUTONOMIC 
FUNCTION TEST
14 23.85 4.071 1.088
ABNORMAL FOR 
AUTONOMIC FUNCTION 
TEST
26 25.75 4.581 0.898
P = 0.201642 NON SIGNIFICANT
4. Metabolic Control of DM
The  correlation  between  metabolic  control  and  autonomic 
dysfunction was not studied since with a single value of FBS & PPBS 
done at the time of examination,  the metabolic control of the patient 
could not be assessed correctly. Metabolic control is also influenced by 
many factors.
5. Resting Tachycardia
Increased heart rate of 90 to 100 beats per minute have been seen 
in  diabetic  patients  with  autonomic  neuropathy  and  sometimes  more 
rapid rates of up to 130/mt occur (Clarke et al - 1982)56. Ewing et al – 
1981,57  found  that  those  with  no  detectable  autonomic  damage  had 
slower heart rates and those with cardiac parasympathetic damage had 
faster rates and those with  additional sympathetic damage had slightly 
slower rates.
In  this  study,  resting  tachycardia  (heart  rate  >  90/mt)  was 
observed in 8 out of 40 patients (20%). Watkins PJ et al58 in their study 
involving 13 diabetics, observed resting tachycardia in 3 of them (23%).
The cut-off  value for  the resting tachycardia  differs  in  various 
studies. Page and Watkins reported resting tachycardia in 100% of the 
subjects studied in their studied when heart rate > 82/mt was taken as 
abnormal.  Applying that  criteria in this study 17 patients (42.5%) of 
diabetics had resting tachycardia.
The  clinical  utility  of  the  knowledge  that  resting  heart  rate  is 
often higher in diabetics due to parasympathetic damage is that such 
patients need to be studied in great detail for CAN since they are prone 
to develop sudden unexpected cardiac arrest more so during procedures 
like  anaesthesia.  Mangoni  AA,  Microti  L,59 showed  that  resting 
tachycardia  decreases  the  distensibility  of  the  vascular  wall  and 
increases  the  risk  of  atherosclerosis,  all  favouring  coronary  artery 
disease.
6. Heart Rate Variability to Deep breathing was abnormal in 37% of 
study subjects. Decreased HRV is considered the earliest indication of 
CAN and its often the most frequent finding in symptomatic CAN. The 
demonstration of the loss of HRV during deep breathing indicates the 
presence of vagal denervation of the heart and is also associated with 
increased  rate  of  progression  of  coronary  atherosclerosis.  Decreased 
vagal activity limits exercise tolerance making these individual prone to 
syncope and predisposition to sudden cardiac death.
7. Abnormal  heart  rate  tests  were  more  often  found than the BP 
tests, which is in concordance with the findings of Watkin’s, Ewing and 
others who postulated that parasympathetic fibers were involved earlier 
than sympathetic fibres. They were found to have significant P value 
correlation with CAN.
Abnormal  BP response  to  standing was found only  in  2 (5%) 
patients & abnormal heart rate on standing in 15(37%) of patients. In 
contrast, according to study conducted by R.C. Gupta M.D, Chittora et 
al  (1995),60  these  tests  were  abnormal  in  64%,  56%  of  patients 
respectively.
The most common abnormal tests in the present study was heart 
rate response to deep breathing and heart rate response to standing, 37% 
each. According to Bergstorm, Sundkuist, et al 1990, the most frequent 
disturbance was an impaired heart rate on deep breathing(E/I ratio) 72% 
& there was no correlation between autonomic neuropathy & duration 
of diabetes, peripheral neuropathy or retinopathy. But the present study 
has  showed  a  significant  correlation  beween  CAN  &  duration  of 
diabetes and with peripheral neuropathy with P values of 0.000611and P 
value of  0.000008 respectively.  In our study no significant  statistical 
correlation was found between CAN and retinopathy & nephropathy. 
Probably this might be due to different sample size of the population 
used in their study and different modes used to detect them.
8. Peripheral Neuropathy
An  increased  incidence  of  autonomic  dysfunction  has  been 
observed in patients with evidence of peripheral neuropathy (80%). This 
is  in  agreement  with  the  findings  of  other  workers  like  Bhatia,61 
Tandon62 etc.
9. Diabetic Retinopathy
The propensity to develop Diabetic Retinopathy is lower in south 
India compared to other population. This may be due to the facts that 
Indians  develop  type  2  DM  at  an  earlier  age  than  the  western 
population,  hence  more  resistance  to  the  development  of  the 
Retinopathy at a younger age and also the  type of diet in south India 
which includes much vegetables, less fat and perhaps antioxidants and 
anti-inflammatory agents like curcummin. Diabetic Retinopathy may be 
present even at the time of diagnosis of type 2 DM due to the insidious 
onset of the disease. Virtually all studies carried out in different parts of 
India have shown an increased prevalence of Diabetic Retinopathy as 
the duration of  diabetes increased.63,64,65 Dandona et al63 reported that 
87.5%  of  those  with  >  15  yrs  duration  of  diabetes  had  Diabetic 
Retinopathy compared with 18.9% of those who had < 15 yrs duration. 
It  has  been  demonstrated  by  the  CURES eye  study  that  severity  of 
retinopathy proportionally  increased  with  longer  duration  of  diabetes 
and that for every five year increase in duration of diabetes the risk for 
Diabetic Retinopathy increased by 1.89 times. In our study the fundus 
abnormality has been found in only 10 patients probably this might be 
due  to  the  sample  size  and  different  tests  used  for  the  detection  of 
retinopathy.
10. Diabetic Nephropathy
In type 2 DM, renal disease is often well-established at diagnosis 
of diabetes and the progression to end stage renal disease occurs faster. 
Persistent  microalbuminuria  is  the  earliest  sign  of  diabetic  kidney 
disease. It has also been found to be an independent predictor of cardio 
vascular morbidity and mortality66.  Mohan et  al,67,68 in his study in a 
diabetic  centre  in  South  India,  observed  a  prevalence  rate  of  36.3% 
microalbuminuria  among  type  2  diabetic  patients.  In  our  study 
microalbuminuria  was  found  in  11  patients  (27.5%)  which  is  in 
concordance with the study mentioned  above.   
11. In UKPDS69 study group it has been found that as many as 37% of 
patients  with  DM  suffer  atleast  1  micro  vascular  complication  and 
atleast  13% have  more  than.  In  our  study  it  has  been  found  in  28 
patients(70%).
12. In a study of 3010 diabetics by Ramachandran A70, the prevalence 
of  microvascular  complications  were  Retinopathy  –  23.7%, 
Nephropathy – 5.5%,Neuropathy – 27.5%.In our study the prevalence of 
Retinopathy – 25%, Nephropathy – 27% and Neuropathy – 55%.
CONCLUSION
1. The  determination  of  incidence  and  prevalence  of  autonomic 
nervous system involvement  in  DM using non-invasive  simple 
tests  is  quite  feasible  and  should  be  done  in  all  diabetics 
registering  in  diabetic  clinics  to  study  the  natural  history  of 
diabetic autonomic neuropathy.
2. These tests can be used in young asymptomatic DM and should 
be  used  for  future  reference  during  surgery  or  intercurrent 
infections of these patients.
3. This study shows the high prevalence of cardiac dysautonomia. 
Most  of  these  patients  remain  asymptomatic.  The incidence of 
cardiac  autonomic  neuropathy  has  also  been found  in  recently 
detected type 2 diabetics.
4. There is a significant  correlation between duration of DM and 
occurrence of cardiac autonomic neuropathy. In this study it  has 
been found that the prevalence of CAN  increases as the duration 
of DM is greater than 6 yrs.
5. Significant correlation has been found between CAN and age of 
the patient. 
6. There  is  a  significant  correlation  between  cardiac  autonomic 
neuropathy  and  peripheral  neuropathy  as  compared  to  other 
microvascular complications like nephropathy and retinopathy.So 
these microvascular complications should be screened as early as 
possible to avoid major morbidity and mortality.
          It can be recommended that a baseline determination of cardiac 
autonomic  function  be  performed  upon  diagnosis  in  type  2  DM 
followed by a yearly repeat test.
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PROFORMA
Name: OP NO:
Age: Ht:
Sex: Wt:
BMI:
Address: WHR:
Occupation:
Duration of DM:
Clinical  Data: Autonomic Neuropathy
1) Light headedness on standing
2) Visual Disturbances on standing
3) Syncope on standing
Peripheral Neuropathy
H/O  Numbness
H/O  Paraesthesias
H/O  Hyperaesthesia
H/O  Lighting pains
Retinopathy
H/O  diminished vision
H/O  double vision
Past His:
HT     duration: Tt
IHD
STD
TB
BR.ASTHMA
TREATMENT HISTORY : OHA
Insulin
Diet : Vegetarian/non-vegetarian
Family History:    
Personal History :          Smoker Alcohol
G/E : Pulse BP - supine:
                     Standing:
Anaemia Lymphadenopathy
Jaundice Pedal edema
Cyanosis Skin
Clubbing 
Systemic Examination
Pulse : RR:
CVS :   Peripheral pulse, Carotid, Radial, Brachial ,Femoral, Popliteal, Dorsalis pedis.
JVP
Apical impulse
LVH-
MURMUR-
S3 or S4
RS:
Abdomen: organomegaly
Briut- Renal/Abdominal Aorta
Tests of Autonomic function
-when was the last medication
-time of waking up
-consumption of Tobacco/Alcohol in last 72 hrs
-consumption of drugs in last 24 hrs
INVESTIGATIONS
Hb%
TC
DC
ESR
Urine R/E
BLOOD SUGAR FBS PPBS
                                                    Hb A1C
BLOOD UREA
SRUM CREATININE
SERUM ELECTROLYTES
ECG
MASTER CHART
TABLE 1
S.No Name Age Sex Ht
cms
Wt
kgs
WHR BMI 
kg / m2
NIDDM
Durn
Tt Postural
Giddiness
Smoking Alcohol
Manisekaran 53 M 173 75 0.9 25 5 Yrs T.GB      -      -          -
Vaithialingam 49 M 173 70 0.9 23.4 2 Yrs T.GB      -      -      -
Joseph Mani 57 M 165 79 0.8 29 3 Yrs T.GB      -      -      -
Ashokan 39 M 161 56 0.9 21.6 4 Yrs T.GB      -      -      -
Ravi 40 M 166 78 0.9 28 8 Yrs T.GB, 
MF
     +      +      +
Ruban 57 M 171 73 0.84 24.9 3 Yrs T.GB      +      -      -
Rathnam 60 M 155 57 0.8 24 2 Yrs T.GB      -      -      -
SenthilKumar 30 M 149 50 0.76 22.5 6 mon MNT      +      +      -
Sathish 23 M 153 44 0.9 18.8 3 mon MNT      -      -      -
Jambulingam 55 M 166 78 0.9 28 7 Yrs T. GB, 
MF
     +      +      +
Anandhan 33 M 148 45 0.78 20.54 1 Yr T.GB      -      -      -
Koteeshwaran 42 M 161 60 0.98 23.14 2 Yrs T.GB      -      -      +
Doss 51 M 162 55 0.96 20.9 5 Yrs T.GB, 
MF
     -      -      -
Vijayalakshmi 45 F 140 67 0.84 34.1 3 Yrs T.GB      -      -      -
Kaveri 40 F 152 54 0.8 23.3 3 Yrs T.GB      -      -      -
Fathimabee 55 F 151 65 0.9 28.5 13Yrs T.GB, 
MF
     +      -      -
M. Pramila 30 F 152 57 0.84 24.67 3 mon MNT      -      -      -
Johenan 60 F 153 50 0.9 21 18 Yrs T.GB, 
MF
     +      -      -
Sakuntala 57 F 146 68 0.8 31.9 10 Yrs T.GB, 
MF
     -      -      -
Gouthaman 47 M 157 55 0.9 22.3 5 Yrs T.GB      -      +      +
Mallika 46 F 155 47 0.91 19.5 7 Yrs T.GB, 
MF
     -      -      -
Premavathy 58 F 156 63 0.83 25.8 8 Yrs T.GB, 
MF
     +      -      -
C. Kala 28 F 149 50 0.86 22.5 2 Yrs T.GB      -      -      -
Karuppiah 65 M 165 72 0.95 26.6 1.5Yrs T.GB      +      +      -
Sekar 32 M 157 58 0.98 23.5 3 Yrs T.GB      -      -      -
Janarthanan 49 M 164 82 0.85 30.4 5 Yrs T.GB      +      +      -
Dhanasekaran 42 M 167 71 0.9 25.4 2 Yrs T.GB      -      -      -
Manisekaran 43 M 160 63 1.0 24.6 3 Yrs T.GB, 
MF
     -      +      +
Ravi 50 M 161 58 1.0 22.3 3 Yrs T.GB      +      -      -
Rajasekar 43 M 157 60 0.95 24.3 1 Yr MNT      -      -      -
Lingamma 48 F 155 90 0.82 37.4 6 Yrs T.GB, 
MF
     -      -      -
Ramamoorthi 58 M 164 70 0.97 26 3 Yrs T.GB      -      -      -
Pandian 51 M 161 60 0.98 23.16 2 Yrs T.GB      -      +      -
Kamatchi 37 F 159 41 0.84 16.41 1 Yr T.GB      -      -      -
R. Lakshmi 48 F 140 67 0.84 34.1 4 Yrs T.GB, 
MF
     +      -      -
S.No Name Age Sex Ht
cms
Wt
kgs
WHR BMI 
kg / m2
NIDDM
Durn
Tt Postural
Giddiness
Smoking Alcohol
T. Lakshmi 45 F 171 57 0.89 19.4 2 Yrs T.MF      -      -      -
Isaac Madhava 
Rajan
35 M 157 64 0.83 25.9 1.5Yrs T.GB, 
MF
     -      -      +
Lakshmi 43 F 158 76 0.9 30.4 1 Yr MNT      -      -      -
Delci Fathima 50 F 157 83 0.9 33.6 5 Yrs T.GB      -      -      -
A. Peter 70 M 167 63 0.9 22.5 10 Yrs T.GB, 
MF
     +      -      -
TABLE - 2
S.No Name
RHR 
per 
min.
Cardiac Autonomic Function Tests
Result of 
CAN
Peripheral
NeuropathyE/I
Ratio
30/15
Rati
o
Valsalva
Ratio
Fall in 
Sys BP
Inc in 
dias BP
1 Manisekaran 78 1.87 1.03 2.11 19 16 Atypical Moderate
2 Vaithialingam 70 1.30 1.27 1.40 5 16 Normal       -
3 Joseph Mani 70 1.2 1.01 1.21 10 18 Normal       -
4 Ashokan 80 1.23 1.06 1.12 4 13 Atypical       -
5 Ravi 72 1.0 1.75 1.08 2 19 Definite Moderate
6 Ruban 76 1.16 1.04 1.07 6 17 Early Mild
7 Rathnam 81 1.05 1.04 1.26 8 20 Early       -
8 SenthilKumar 100 1.44 0.99 1.31 4 18 Early Mild
9 Sathish 76 2.42 1.19 1.24 2 20 Normal       -
10 Jambulingam 81 1.08 0.96 1.00 10 20 Definite Moderate
11 Anandhan 83 1.54 1.24 1.37 3 11 Normal       -
12 Koteeshwaran 75 1.29 1.06 1.36 5 20 Normal       -
13 Doss 86 1.06 1.07 1.27 10 16 Early Moderate
14 VijayaLakshmi 83 1.34 0.87 2.08 3 17 Early Mild
15 Kaveri 90 1.22 1.06 1.67 10 18 Normal       -
16 Fathimabee 94 1.05 0.96 1.07 30 10 Severe Mild
17 M. Pramila 81 1.52 1.21 2.00 5 16 Normal       -
18 Johenan 112 1.04 1.00 1.10 16 12 Severe Mild
19 Sakuntala 95 1.01 1.00 1.12 14 8 Severe Moderate
20 Gouthaman 80 1.08 1.04 1.74 10 18 Early Moderate
Contd...
S.No Name RHR per min.
Cardiac Autonomic Function Tests Result
of CANE/I
Ratio
30/15
Ratio
Valsalva
Ratio
Fall in Sys 
BP
Inc in 
dias BP
21 Mallika 100 1.12 1.04 1.14 3 12 Atypical
22 Premavathy 96 1.00 0.88 1.13 3 16 Definite
23 C. Kala 82 1.32 0.91 1.56 2 20 Early
24 Karuppiah 104 1.00 1.00 1.34 10 16 Definite
25 Sekar 74 1.26 1.04 1.53 2 18 Normal
26 Janarthanan 90 1.04 0.99 1.21 10 20 Definite
27 Dhanasekaran 83 1.27 1.05 1.25 4 18 Normal
28 Manisekaran 75 1.35 0.95 1.37 10 18 Early
29 Ravi 76 1.06 1.06 1.28 3 16 Early
30 Rajasekar 86 1.67 1.04 1.38 6 12 Normal
31 Lingamma 86 1.01 0.98 1.29 10 16 Definite
32 Ramamoorthi 85 1.20 1.00 2.23 10 20 Early
33 Pandian 80 1.22 1.00 1.26 4 18 Early
34 Kamatchi 70 1.49 1.06 1.3 8 16 Normal
35 R. Lakshmi 76 1.28 1.03 1.24 12 18 Atypical
36 T. Lakshmi 71 2.16 1.04 1.26 9 17 Normal
37 Isaac Madhava 
Rajan
79 2.03 1.08 2.9 12 18 Normal
38 Lakshmi 82 1.48 1.06 2.8 4 14 Normal
39 Delci Fathima 84 1.05 1.06 1.25 10 20 Early
40 A. Peter 110 1.00 0.8 1.1 33 0 Severe
TABLE - 3
S.No FBS mg/dl
PPBS 
mg/dl
Sr Urea 
mg/dl
Sr Creatinine 
mg/dl Urine Albumin
1 230 288 23 0.8 +
2 115 200 22 0.9 -
3 120 214 20 0.7 -
4 141 205 44 2.8 +
5 150 212 40 2.5 +
6 130 160 22 0.8 -
7 152 240 24 0.8 -
8 170 210 21 0.7 -
9 110 160 19 0.6 -
10 240 280 20 0.8 -
11 118 192 20 0.75 -
12 92 210 22 0.73 -
13 192 226 26 0.8 -
14 164 200 42 1.7 +
15 120 180 22 0.8 -
16 167 378 38.5 1.6 +
17 119 182 20 0.9 -
18 140 180 22 0.8 -
19 92 214 46 1.9 ++
20 166 214 22 0.92 -
Contd...
S.No FBS mg/dl
PPBS 
mg/dl
Sr Urea 
Mg/dl
Sr Creatinine 
mg/dl Urine Albumin
21 140 167 20 0.7 -
22 240 288 42 1.9 +
23 180 260 20 0.8 -
24 190 270 26 0.9 -
25 126 244 21 0.7 -
26 154 219 24 0.9 -
27 125 215 23.5 0.8 -
28 124 200 44 1.9 ++
29 142 188 24 0.8 -
30 100 260 22 0.9 -
31 167 230 42 1.7 +
32 110 210 20 0.9 -
33 140 260 21 0.8 -
34 90 170 19 0.8 -
35 116 180 46 1.7 ++
36 86 120 20 0.9 -
37 136 166 44 1.9 +
38 120 180 26 0.8 -
39 146 216 42 0.7 -
40 110 246 19 0.9 -
ABBREVIATIONS
DM - Diabetes Mellitus
WHO - World Health Organization
UKPDS - United Kingdom Prospective Diabetes Study
CANS - Cardiac Autonomic Neuropathy System Analyzer
IFG - Impaired Fasting Glucose
IGT - Impaired Glucose Tolerance 
CNS - Central Nervous System
GABA - Gamma Amino Butyric Acid
DAN - Diabetic Autonomic Neuropathy
IDDM - Insulin Dependent Diabetes Mellitus
NIDDM - Non Insulin Dependent Diabetes Mellitus
IGF - Insulin like Growth Factor
AGE - Advanced Glycosylation End Products
DNA - Deoxy Ribonucleic Acid
PARP - Poly ADP - Ribose Polymerase
NAD+ - Nicotine Adenine Dinucleotide
ATP - Adenosine Triphosphate
ADP - Adenosine Diphosphate
NGF - Nerve Growth Factor
CAN - Cardiac Autonomic Neuropathy
bpm - beats per minute
BP - Blood Pressure
ECG - Electrocardiogram
min - Minute
mmHg - mm of Mercury
sec - Seconds
VPT - Vibration Perception Threshold
V - Voltage
DCCT - Diabetes Control and Complications Trial
Yr - Year
BMI - Body Mass Index
WHR - Waist Hip Ratio
HRV - Heart Rate Variability
ROS - Reactive Oxygen Species
CURES - Chennai Urban Rural Epidemiological Study
RHR - Resting Heart Rate
Inc - Increase
N - Normal
Sys BP - Systolic Blood Pressure
dias BP - Diastolic Blood Pressure
+ - Positive
- - Negative
Sr - Serum
Ht - Height
Wt - Weight
H/O - History of
HT - Hypertension
IHD - Ischemic Heart Disease
STD - Sexually Transmitted Disease
TB - Tuberculosis
BR.Asthma - Bronchial Asthma
OHA - Oral Hypoglycemic Agent
G/E - General Examination
RR - Respiratory Rate
JVP - Jugular Venous Pulse
LVH - Left Ventricular Hypertrophy
RS - Respiratory System
Hrs - Hours
Hb% - Haemoglobin
TC - Total Count
DC - Differential Count
ESR - Erythrocyte Sedimentation Rate
R/E - Routine Examination
g - Grams
MNT - Medical Nutritional Therapy
GB - Glibenclamide
MF - Metformin
NFkB - Nuclear factor k B
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